BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Singleton DC, Mowday AM, Guise CP, et al. (2021) Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411 leading to therapeutic benefit. Cancer Gene Therapy |
| Liew LP, Singleton DC, Wong WW, et al. (2019) Hypoxia Activated Prodrugs of PERK Inhibitors. Chemistry, An Asian Journal |
| McIntyre A, Hulikova A, Ledaki I, et al. (2016) Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research |
| Singleton DC, Rouhi P, Zois CE, et al. (2014) Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene |
| Pettersen EO, Ebbesen P, Gieling RG, et al. (2014) Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry. 1-33 |
| Singleton DC, Harris AL. (2013) Microenvironmental induced essentiality of autophagy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2791-3 |
| Kumar K, Wigfield S, Gee HE, et al. (2013) Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine (Berlin, Germany). 91: 749-58 |
| Pike LR, Singleton DC, Buffa F, et al. (2013) Transcriptional up-regulation of ULK1 by ATF4 contributes to cancer cell survival. The Biochemical Journal. 449: 389-400 |
| Singleton DC, Harris AL. (2012) Targeting the ATF4 pathway in cancer therapy. Expert Opinion On Therapeutic Targets. 16: 1189-202 |
| Dachs GU, Hunt MA, Syddall S, et al. (2009) Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules (Basel, Switzerland). 14: 4517-45 |